IRGM-Mediated Autophagy Complex Stabilization for Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The molecular mechanism of IRGM's function in autophagy remains unknown, despite its significance in human populations and its role as a genetic risk factor for inflammatory diseases like Crohn's disease and tuberculosis, and current methods lack the ability to monitor autophagy modulation during treatments.
Innovation Solution
IRGM interacts with key autophagy regulators such as ULK1, Beclin 1, and NOD2, forming molecular complexes that stabilize the core autophagy machinery, and modulators like double-stranded RNA and muramyl dipeptide are used to treat inflammatory and antimicrobial diseases by modulating autophagy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IRGM is used to control autophagy for treating inflammatory diseases, then therapeutic efficacy is improved, but the molecular mechanism remains unknown and difficult to detect
Solution Approach 1:
The patent introduces molecular complexes as intermediaries between IRGM and the core autophagy machinery. IRGM forms complexes with ULK1, Beclin 1, and NOD2, which serve as mediators to transmit and stabilize autophagy initiation signals. This intermediary mechanism makes the previously unknown molecular pathway detectable and understandable while maintaining therapeutic efficacy.
2Ease of manufacture
If current methods are used to treat inflammatory diseases, then treatment is provided, but ability to monitor autophagy modulation during treatment is lacking
Solution Approach 1:
The patent establishes a feedback mechanism by identifying specific molecular complexes (IRGM-ULK1-Beclin 1-NOD2) that can be detected to monitor autophagy modulation during treatment. This allows clinicians to assess whether the treatment is effectively modulating autophagy and adjust therapy accordingly, providing real-time feedback on treatment efficacy at the molecular level.
3Reliability
If IRGM modulators are used to enhance antimicrobial functions, then disease treatment is improved, but complexity of the molecular complexes increases
Solution Approach 1:
The patent merges multiple molecular functions into a coordinated complex. IRGM, ULK1, Beclin 1, and NOD2 are combined into a functional molecular complex that integrates autophagy initiation, stabilization, and antimicrobial responses. This merging allows the system to achieve enhanced antimicrobial function through coordinated action of multiple components rather than isolated actions.
Data Source
AI summary
The present invention relates to the discovery that IRGM, encoded by a uniquely human gene which confers risk for inflammatory diseases, affects autoophagy through a hitherto unknown mechanism. The present invention shows that IRGM controls autophagy and that IRGM modulators, in particular, double-stranded RNA, including poly I:C, poly-UG (polyUGUGU) and polyICLC and muramyldipeptide and related analogs of same, including N-acetyl muramyl-L-alanyl-D-isoglutamine (Muramyl dipeptide or MDP) and numerous other compounds as identified herein, which may be used alone, in combination, or in combination with alternative autophagy modulators and additional bioactive agents to provide effective therapies for a number of diseases, including cancer, bacterial infections and inflammatory diseases, especially including tuberculosis infections and Crohn's disease, among others. The present invention is also directed to compositions and methods for treating inflammatory or autophagy-related diseases including diseases which cause excessive inflammation in patients.